Literature DB >> 16344434

Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation.

Ferdinando Bottoni1, Amedeo Massacesi, Mario Cigada, Francesco Viola, Ilenia Musicco, Giovanni Staurenghi.   

Abstract

OBJECTIVE: To report the management of retinal angiomatous proliferation (RAP), a recently described intraretinal neovascular lesion occurring in age-related macular degeneration.
METHODS: This was a retrospective review of consecutive patients with age-related macular degeneration who underwent treatment of RAP from January 1, 2000, through January 31, 2003. Inclusion criteria were age 55 years or older, signs of age-related macular degeneration, and diagnosis of RAP based on dynamic indocyanine green angiography. Baseline angiograms were reviewed and RAP was classified into the following 3 stages: stage 1, intraretinal neovascularization, early stage; stage 2, subretinal neovascularization, middle stage; and stage 3, choroidal neovascularization, late stage. Treatment and concomitant treatment results were assessed separately for each RAP stage. The clinical data were statistically analyzed (chi2 test and analysis of variance) for 2 main outcome measures--complete obliteration of the lesion and final visual acuity.
RESULTS: Eighty-one patients (99 eyes) with 104 RAPs were identified. Forty-two lesions were at stage 1, 42 at stage 2, and 20 at stage 3. The following 5 treatments were performed: direct laser photocoagulation of the vascular lesion, laser photocoagulation of the feeder retinal arteriole, scatter "gridlike" laser photocoagulation, photodynamic therapy, and transpupillary thermotherapy. Complete obliteration of RAP was achieved in about 24 (57.1%) of the stage 1 lesions (direct laser photocoagulation of the vascular lesion, 73% success rate; photodynamic therapy, 45%), 11 (26.2%) of the stage 2 lesions (scatter gridlike laser photocoagulation, 38% success rate; direct laser photocoagulation of the vascular lesion, 17%), and only 3 (15.0%) of stage 3 lesions (P = .001). Predictive factors with a significant effect on final visual acuity were initial visual acuity (P = .003) and early lesion stage (P = .04). Best final visual acuity was 0.41 (mean, direct laser photocoagulation of the vascular lesion in stage 1) and 0.39 (mean, photodynamic therapy in stage 1), with a mean decrease of 2.5 and 3 lines from baseline, respectively.
CONCLUSIONS: Treatment of RAP remains difficult. Early detection of the lesion and subsequent direct conventional laser photocoagulation seems to be associated with better anatomical and functional outcome. Once the vascular complex is well established, anatomical closure is rarely achieved. Further study is warranted to assess the long-term efficacy and the need for re-treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344434     DOI: 10.1001/archopht.123.12.1644

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  34 in total

1.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

2.  The role of Vldlr in intraretinal angiogenesis in mice.

Authors:  Chun-Hong Xia; Eric Lu; Haiquan Liu; Xin Du; Bruce Beutler; Xiaohua Gong
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-22       Impact factor: 4.799

3.  The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization.

Authors:  Amedeo L Massacesi; Laura Sacchi; Fulvio Bergamini; Ferdinando Bottoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-25       Impact factor: 3.117

Review 4.  Animal models of ocular angiogenesis: from development to pathologies.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; Jing Chen
Journal:  FASEB J       Date:  2017-07-24       Impact factor: 5.191

5.  Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.

Authors:  Han Joo Cho; Tae Gon Lee; Sang Youn Han; Hyoung Seok Kim; Jae Hui Kim; Jung Il Han; Young Ju Lew; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-01       Impact factor: 3.117

6.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

Review 7.  Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.

Authors:  Mohammad Hossein Jabbarpoor Bonyadi; Mehdi Yaseri; Mortaza Bonyadi; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2016-12-22       Impact factor: 2.031

8.  [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].

Authors:  A Lommatzsch; B Heimes; M Gutfleisch; G Spital; M Dietzel; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

9.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

10.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.